HomeCompareRVXCF vs PFE

RVXCF vs PFE: Dividend Comparison 2026

RVXCF yields 2298.85% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RVXCF wins by $36577739038.80M in total portfolio value
10 years
RVXCF
RVXCF
● Live price
2298.85%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$36577739038.85M
Annual income
$33,694,466,973,692,370.00
Full RVXCF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — RVXCF vs PFE

📍 RVXCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRVXCFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RVXCF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RVXCF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RVXCF
Annual income on $10K today (after 15% tax)
$195,402.30/yr
After 10yr DRIP, annual income (after tax)
$28,640,296,927,638,510.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, RVXCF beats the other by $28,640,296,927,616,190.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RVXCF + PFE for your $10,000?

RVXCF: 50%PFE: 50%
100% PFE50/50100% RVXCF
Portfolio after 10yr
$18288869519.45M
Annual income
$16,847,233,486,859,314.00/yr
Blended yield
92.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

RVXCF
No analyst data
Altman Z
-94.1
Piotroski
1/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RVXCF buys
0
PFE buys
0
No recent congressional trades found for RVXCF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRVXCFPFE
Forward yield2298.85%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$36577739038.85M$49.6K
Annual income after 10y$33,694,466,973,692,370.00$26,258.71
Total dividends collected$36375156338.99M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RVXCF vs PFE ($10,000, DRIP)

YearRVXCF PortfolioRVXCF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$240,585$229,885.06$9,153$693.39+$231.4KRVXCF
2$5,426,296$5,168,870.07$8,593$849.25+$5.42MRVXCF
3$114,761,014$108,954,877.01$8,336$1,066.78+$114.75MRVXCF
4$2,276,338,467$2,153,544,182.26$8,437$1,384.80+$2276.33MRVXCF
5$42,357,698,654$39,922,016,494.37$9,013$1,875.40+$42357.69MRVXCF
6$739,586,041,815$694,263,304,255.43$10,306$2,680.72+$739586.03MRVXCF
7$12,120,492,876,395$11,329,135,811,652.31$12,820$4,101.38+$12120492.86MRVXCF
8$186,486,946,005,072$173,518,018,627,329.40$17,673$6,826.70+$186486945.99MRVXCF
9$2,694,646,789,868,656$2,495,105,757,643,229.00$27,543$12,591.86+$2694646789.84MRVXCF
10$36,577,739,038,851,830$33,694,466,973,692,370.00$49,560$26,258.71+$36577739038.80MRVXCF

RVXCF vs PFE: Complete Analysis 2026

RVXCFStock

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.

Full RVXCF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this RVXCF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RVXCF vs SCHDRVXCF vs JEPIRVXCF vs ORVXCF vs KORVXCF vs MAINRVXCF vs JNJRVXCF vs MRKRVXCF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.